[HTML][HTML] Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
[HTML][HTML] Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …
genomic landscapes and biological functions, the treatment of PCa continues to improve …
Relugolix in the management of prostate cancer
Introduction Relugolix is the first oral gonadotrophin-releasing hormone (GnRH) receptor
antagonist. Based on the phase III HERO trial results, relugolix received Food and Drug …
antagonist. Based on the phase III HERO trial results, relugolix received Food and Drug …
斑马鱼急性无机砷暴露后肝脏差异表达基因的生物信息学分析.
张新生， 张越， 孙纳 - Chinese Journal of Bioinformatics, 2024 - search.ebscohost.com
为确定治疗新型冠状病毒(SARS⁃ CoV⁃ 2) 感染的候选药物, 开展了针对SARS⁃ CoV⁃ 2
的药物虚拟筛选研究. 以SARS⁃ CoV⁃ 2 的刺突蛋白(S 蛋白) 和3CL 蛋白酶(主蛋白酶) …
的药物虚拟筛选研究. 以SARS⁃ CoV⁃ 2 的刺突蛋白(S 蛋白) 和3CL 蛋白酶(主蛋白酶) …
[HTML][HTML] Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone receptor antagonist, in healthy men: a randomized …
X Li, F Sun, X Zhang, P Lin, K Shen, Y Shen, L Ma… - BMC medicine, 2023 - Springer
Abstract Background Gonadotropin-releasing hormone (GnRH) antagonists are a promising
therapeutic approach for treating hormone-dependent prostate cancer. Currently, the …
therapeutic approach for treating hormone-dependent prostate cancer. Currently, the …
[Retracted] Effectiveness of GnRH Antagonists and Agonists in Patients with Hormone‐Sensitive Prostate Cancer: A Retrospective Study
Z Liu, C Yang, X Zeng, C Ke, J Tian… - Applied Bionics and …, 2022 - Wiley Online Library
Objective. To assess the effectiveness of gonadotropin‐releasing hormone (GnRH)
antagonists and agonists in the treatment of patients with hormone‐sensitive prostate cancer …
antagonists and agonists in the treatment of patients with hormone‐sensitive prostate cancer …
Investigation of the GnRH antagonist degarelix isomerization in biological matrices
L Ferrazzano, A Tolomelli, I Guryanov… - Pharmacology …, 2023 - Wiley Online Library
One of the main objectives of peptide drug design is the improvement of peptide
pharmacokinetics with maintaining biological activity, which can be achieved by the complex …
pharmacokinetics with maintaining biological activity, which can be achieved by the complex …